VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Exelixis, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for further evaluation of cabozantinib, Exelixis' lead compound, in a variety of solid tumors.

28 Nov 2011

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

Exelixis, Inc. today announced the initiation of an investigator-sponsored trial of cabozantinib in women with hormone receptor-positive breast cancer with bone metastases.

21 Nov 2011

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.

19 Nov 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

14 Nov 2011

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Exelixis, Inc. today reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

14 Nov 2011

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Circadian Technologies Limited announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug application from the U.S. Food and Drug Administration to initiate clinical trials of VGX-100.

31 Oct 2011

Researchers uncover biochemical signals that trigger generation of new lung alveoli

Researchers at Weill Cornell Medical College say they have taken an important step forward in their quest to "turn on" lung regeneration -- an advance that could effectively treat millions of people suffering from respiratory disorders.

29 Oct 2011

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Regeneron Pharmaceuticals, Inc. today announced that detailed clinical data from the positive Phase 2b portion of the seamless Phase 2/3 MOBILITY trial of sarilumab in rheumatoid arthritis (RA) will be presented at a late-breaking poster session at the upcoming American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place from November 5-9 in Chicago.

28 Oct 2011

Macular degeneration drug may cause increased IOP

Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye. It led to a retrospective study and findings that will be presented at the American Academy of Ophthalmology in Orlando.

24 Oct 2011

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Exelixis, Inc. today reported top-line results from the ongoing phase 3 clinical trial of cabozantinib in patients with advanced medullary thyroid cancer (MTC), known as the EXAM trial.

24 Oct 2011

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular (“wet”) Age-related Macular Degeneration (AMD).

24 Oct 2011

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.

24 Oct 2011

Dual role for VEGF in regulating skin cancer stem cells and tumor progression

In a study published in Nature, researchers lead by Cédric Blanpain, MD/PhD, FNRS/FRS researcher and WELBIO investigator at the IRIBHM, Université libre de Bruxelles, Belgium, in collaboration with the groups of Peter Carmeliet (VIB/K.U.Leuven) and Jody J. Haigh (VIB/UGent) identify a new role for Vascular Endothelial Growth Factor (VEGF) in regulating skin cancer stem cells.

21 Oct 2011

VEGF protein appears to prevent progression of spinocerebellar ataxia type 1

A protein that promotes the growth of neurons and blood vessels appears to stop the progression of a genetic disease that causes degeneration of the cerebellum, according to new preclinical Northwestern Medicine research published in Nature Medicine.

18 Oct 2011

Reversing low VEGF levels may potentially treat patients with SCA1

A groundbreaking study in the journal Nature Medicine suggests what could become the first effective treatment for a debilitating and fatal disease of the central nervous system called SCA1.

18 Oct 2011

Exercise stimulates two beneficial proteins in women before and during pregnancy

Although exercise is generally considered to be a good thing for people with high blood pressure, it has traditionally been considered too risky for women who are also pregnant. Some studies suggest that exercise has benefits such as decreasing the risk of women developing preeclampsia, a condition that raises blood pressure to dangerously high levels but how this might happen has remained unknown.

15 Oct 2011

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Sangamo BioSciences, Inc. today announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo.

3 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011

VEGF News and Research

Further Reading

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Researchers uncover biochemical signals that trigger generation of new lung alveoli

Regeneron announces positive results from sarilumab Phase 2b trial on RA

Macular degeneration drug may cause increased IOP

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Dual role for VEGF in regulating skin cancer stem cells and tumor progression

VEGF protein appears to prevent progression of spinocerebellar ataxia type 1

Reversing low VEGF levels may potentially treat patients with SCA1

Exercise stimulates two beneficial proteins in women before and during pregnancy

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry focus eBook - The Digital Laboratory (4th edition)

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation